Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)’s share price shot up 5.9% during mid-day trading on Friday . The stock traded as high as $4.52 and last traded at $4.46, with a volume of 1,549,901 shares trading hands. The stock had previously closed at $4.21.

A number of equities research analysts have recently commented on KERX shares. Ladenburg Thalmann upped their target price on shares of Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 20th. Maxim Group reaffirmed a “buy” rating and issued a $9.00 target price (up from $7.00) on shares of Keryx Biopharmaceuticals in a report on Friday, July 8th. Finally, Stifel Nicolaus cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and a consensus price target of $8.79.

The stock’s 50-day moving average price is $6.55 and its 200 day moving average price is $5.21. The company’s market capitalization is $475.13 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.14. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. The business’s revenue for the quarter was up 272.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.26) earnings per share. Equities analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($1.21) EPS for the current year.

In other news, CFO Scott A. Holmes sold 4,935 shares of Keryx Biopharmaceuticals stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new stake in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned about 0.32% of Keryx Biopharmaceuticals as of its most recent SEC filing.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.